384 filings
Page 3 of 20
6-K
72l p8qsaqkz9a4
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
6-K
hpm4 igsjb
16 Oct 23
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
4:01pm
6-K
4p72dk8q6
12 Oct 23
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
8:48am
6-K
g1cbt c2cptzcddk7
3 Oct 23
SciSparc Granted European Patent for its Core Technology
7:35am
6-K
gtt8o9rl513lgptyb79
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
bon085w
21 Sep 23
SciSparc Announces 1-for-26 Reverse Share Split
6:31am
6-K
440ikbgw
19 Sep 23
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
6:16pm
6-K
dwr4aktim3tf1gu9g5b
7 Sep 23
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
4:01pm
6-K
pcmcxer3wib0022 pie
18 Aug 23
Report of Foreign Private Issuer
4:01pm
6-K
z42p7ln7zs
14 Aug 23
Supplemental Proxy Statement
5:29pm
6-K
gtdxcvxoyy2namqmxuv
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
424B5
6x6eu8xd6l5hxkvj2zq
14 Aug 23
Prospectus supplement for primary offering
9:14am
424B3
5054k
10 Aug 23
Prospectus supplement
6:32am
6-K
09yq1spk549vid t5zq
9 Aug 23
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
7:30pm
424B3
5s1c 9e427eqvps
9 Aug 23
Prospectus supplement
4:01pm
6-K
f4hsxm9c2t
2 Aug 23
Report of Foreign Private Issuer
12:00am
6-K
1nm1nktqps eqympbvl1
17 Jul 23
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
8:00am
6-K
gtdrw if9p1j
11 Jul 23
Report of Foreign Private Issuer
4:16pm
6-K
zn2joxx45216c1uwk
30 Jun 23
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
4:10pm
6-K
wnw d6y9d5cu9
26 Jun 23
Report of Foreign Private Issuer
4:04pm